

ISCI, Volume 10

## **Supplemental Information**

**CRISPR/Cas9 deletions in a conserved exon  
of *Distal-less* generates gains and losses in a  
recently acquired morphological novelty in flies**

**Gowri Rajaratnam, Ahiraa Supeinthiran, Rudolf Meier, and Kathy F.Y. Su**

1 **Supplemental Information**

2

3 **CRISPR/Cas9 deletions in a conserved exon of *Distal-less* generates gains and losses in a**  
4 **recently acquired morphological novelty in flies.**

5

6 **Authors:**

7

8 Gowri Rajaratnam<sup>1</sup>, Ahiraa Supeinthiran<sup>3</sup>, Rudolf Meier<sup>1,2\*</sup> and Kathy F.Y. Su<sup>1\*</sup>

9 <sup>1</sup> Department of Biological Sciences, National University of Singapore, Singapore

10 <sup>2</sup> Lee Kong Chian Natural History Museum, Singapore

11 <sup>3</sup> University of Toronto Scarborough, Canada

12 \*corresponding author

13

14

## 15 **Transparent Methods**

### 16 **Fly cultures**

17 *Themira biloba* fly cultures were kept at a constant temperature of 23 °C with a 12-hour light  
18 and dark cycle and maintained on a diet of duck and bovine dung.

### 19 **Preparation of guide RNAs**

20 Three CRISPR guide RNAs targeting Exon 2 and Exon 3 (homeodomain) were designed for  
21 *T. biloba*. *T. biloba* assembled transcriptome was downloaded from NCBI, Accession number  
22 PRJNA218740 (Melicher et al., 2014). Using CLC Genomics Workbench we searched for  
23 *Dll* transcript sequences within the *T. biloba* transcriptome using BLASTn against *D.*  
24 *melanogaster Dll*. Using CLC Genomics Workbench we then designed guides targeting Exon  
25 2 and Exon 3 of *T. biloba Dll*. We searched for regions that contained GGN<sub>19</sub>NGG. The  
26 guides were screened for off-target effects using a blastn query against the assembled *T.*  
27 *biloba* transcriptome (Melicher et al., 2014). Specifically, for sgRNA-2B, this search did not  
28 find any 100% off-target matches. However, it did identify three hits with a hit-length of 13  
29 bp and E-values around 1E-3. Further investigation of these hits reveal that they do not flank  
30 a PAM site and so are unlikely to result in off-target effects (Supplementary table 2).

31 The single guide RNA (sgRNA) templates were synthesised artificially using **gBlocks® Gene**  
32 **Fragments (Integrated DNA Technologies)**. Following *in vitro* transcription of the gblocks  
33 DNA template with a T7 polymerase (New England Biolabs), the sgRNAs were purified  
34 using the TURBO DNase kit followed by the Qiagen RNeasy kit. *In vitro* Cas9 cleavage  
35 assays were then carried out to test the guide's ability to cut the target DNA fragment in the  
36 presence of Cas9 protein (PNAbio).

### 37 **Microinjection**

38 Eggs were extracted from the egg-laying substrate after 4 hours, rinsed gently, aligned onto a  
39 coverslip, and covered with a thin layer of oil to prevent desiccation. 1ul of 1ug/ul Cas9  
40 protein (PNAbio) was mixed with 1ul of 1ug/ul of sgRNA and injected into the posterior of  
41 the eggs using a 76mm needle. Needles were pulled fresh with a Sutter P-97 Flaming/Brown  
42 type micropipette puller. To overcome the lethality of a *Dll* knockdown in early  
43 embryogenesis (Cohen and Jürgens, 1989), the protocol was optimized to reduce the number

44 of mosaic mutant cells generated by injecting 4-hour old embryos with a reduced volume of  
45 the sgRNA/Cas9 complex.

46 The injected eggs were then rinsed thoroughly and kept in a moist chamber for 24 hours. The  
47 emerging larvae were then picked out and placed into petri dishes of bovine dung to develop.  
48 After 8-10 days, the pupae were recovered and left to develop in a moist chamber. The  
49 emerging adults were allowed to completely sclerotize for 3 days before they were screened  
50 for mutations. The mutant individuals were then preserved in 70% ethanol for imaging and  
51 DNA extraction. Images were obtained using a Visionary Digital Imaging system.

## 52 **Genotyping of Mutations**

53 QuickExtract (Bioline) solution was used to extract gDNA from mutant tissue dissected from  
54 the vicinity of affected structure. Extracted DNA was used to amplify the gene region of  
55 interest (~200 bp fragment). The tarsi of a wildtype *T. biloba* male were dissected and used as  
56 a control for this experiment.

57 PCR products were cleaned up with SureClean and sent for Illumina Miseq (2x301bp)  
58 sequencing at 10,000x coverage (the read count and coverage for each sample is listed in  
59 Supplementary table 3).. These mutations were mostly small deletions within the guide  
60 sequence. To ensure that the mutations observed were not an artefact of PCR or sequencing  
61 error, 3 PCR replicates (with tagged primers, Supplementary table 4) were carried out for all  
62 mutants. The reads for all three replicates were processed separately and combined after  
63 ascertaining that the three most abundant reads for each were identical. This combined  
64 dataset was then used for the quantification of the read count and proportions of mutant  
65 haplotypes for each specimen.

66 The DNA reads were then recovered using an in-house pipeline: the sequences were merged  
67 using PEAR(Zhang et al., 2014) and demultiplexed using an in-house script (Meier et al.,  
68 2016) to generate a fasta file for each PCR product/specimen. The reads were aligned using  
69 MAFFT v7.0 (Kato et al., 2002). Once aligned, the sequences were submitted to the ‘DNA  
70 to haplotype collapser and converter’ Fabox tool.(Villesen, 2007) This generates a table of  
71 haplotypes and read counts as well as a summary of all the haplotypes observed. The three  
72 most abundant haplotypes were recorded (see Supplementary table 3). The most abundant  
73 mutant haplotype for each specimen was used for downstream alignments and comparisons.  
74 The results were also confirmed with CRISPresso (Pinello et al., 2016) (window size set to  
75 30 bp and sequence homology for an HDR occurrence set to 98%). Bioinformatics analysis

76 for ESE sites were performed using ESEfinder (v 3.0)(Cartegni et al., 2003). We used the  
77 weighted matrix values for SRSF1, the human homolog of the Drosophila SF2/ASF at the  
78 threshold of 1.956(Smith et al., 2006).

## 79 **Control Injections**

80 To rule out off-target effects and injection artefacts, 1004 embryos were injected with 500ng  
81 of Cas9 alone. Note that the control injections were used to train students in the  
82 microinjection technique and as such, the mortality for the control injections is high overall  
83 due to mechanical damage. No mutants of any type were observed for the surviving adults.  
84 Adults from control injections were genotyped and no mutations were observed.

## 85 **Exon-skipping**

86 In order to detect if exon skipping was occurring when Exon 2 was targeted, RNA was  
87 extracted from two independent replicates of 160 injected embryos (C1 and C2) as well as  
88 two wildtype replicates using TRIzol (Invitrogen). The RNA was transcribed into cDNA  
89 using the ProtoScript II First Strand cDNA synthesis kit (New England Biolabs). The gene  
90 region of interest was then amplified. The same volume of product was loaded onto a 1%  
91 agarose gel for both the wildtype and mutant replicates. A shorter band (~ 400bp) was  
92 observed for only C1 and C2 and not the wildtype replicates (Fig.5A). The shorter band was  
93 then sent for Sanger sequencing, where a transcript lacking Exon 2 was found.

## 94 **Protein analysis**

95 PCR was used to generate the template needed for *in vitro* protein synthesis. Primers specific  
96 to the start and stop codons of *Dll* coding sequence were used to add specific adaptor  
97 sequences (see PURExpress manual and supplementary table 4) to the *Dll* coding sequence  
98 lacking Exon 2. A T7 promoter and ribosome binding site were added to the upstream of the  
99 start of *Dll* translation and a 35-mer loop structure was added to the 3' of *Dll* coding  
100 sequence (See PURExpress manual and supplementary table 4 for primer sequences). This  
101 PCR product was purified using the Qiagen PCR purification kit and used as a template for *in*  
102 *vitro* protein synthesis with the PURExpress kit (New England Biolabs). Both the *Dll*  
103 template as well as a control reaction with no template were set-up and processed in the same  
104 way. 8ul of this synthesised protein product was run out on an SDS-PAGE gel (10% Mini-  
105 PROTEAN® TGX™ Precast Gel) at 120V for 90 minutes, along with the control. The >30  
106 kDa band, representing the synthesized *Dll* protein, was excised from the gel and sent for

107 analysis on the Triple TOF 5600 (Ab SCIEX). Unfortunately, we noticed that although the  
108 same amount of the reaction was loaded onto the gel, the control reaction appeared fainter  
109 than the reaction with the *Dll* template.

110 As an additional measure to rule out the possibility that the >30kDa band was simply not  
111 observed in the fainter control, we excised out the corresponding area in the control gel lane  
112 and sent it in for mass spectrometry analysis as well.

113 The Mass Spectra raw data was searched against the NCBI *D. melanogaster* protein database  
114 and the *E. coli* database supplemented with the *Dll* predicted protein sequence for *Themira*  
115 *biloba* with ProteinPilot® v4.5 (Revision: 1656; Paragon Algorithm: 4.5.0.0, 1654). Searches  
116 were run as thorough identification searches, specifying tryptic digestion and cys-alkylation  
117 (Iodoacetamide). For the *Dll* protein sample, peptides were found with strong matches to an  
118 alternative initiation codon as well as to the homeodomain and Exon 4 (Supplementary  
119 Figure 3). No confident peptide matches were found for the analogous control sample  
120 (supplementary file in Mendeley resource).

#### 121 ***Distal-less* isoform characterisation**

122 In order to qualitatively characterise the alternative splice forms of *Dll* present in both mutant  
123 and wildtype individuals, targeted long-read isoform circular consensus  
124 sequencing (Gonzalez-Garay, 2016) was conducted for 4 individuals. 405 embryos were  
125 injected with sgRNA-2A (targeting the second ESE site within Exon 2). After 7 days, total  
126 RNA and DNA was isolated from 12 injected 3<sup>rd</sup> instar larvae using TRIzol® Reagent  
127 (Invitrogen). cDNA was synthesised using the ProtoScript II First Strand cDNA synthesis kit  
128 (New England Biolabs) for each of these individuals and an in-vitro cleavage assay was  
129 performed to identify the mutant specimens. Two individuals (M4 and M6) were observed  
130 with mutations and exon skipping.

131 Similarly, RNA was extracted and used for cDNA synthesis for two wildtype 3<sup>rd</sup> instar larvae  
132 (WT1 and WT2). Primers were designed within the *Dll* locus to amplify and capture *Dll*  
133 specific splice forms (Supplementary Table 4). 5' phosphorylated forward primers were  
134 designed in *Dll* exon 1 (5' UTR) and reverse 16bp-tagged primers were designed for *Dll* exon  
135 7 (3' UTR). A 16bp tag unique to each specimen was attached to the 3' end of the reverse  
136 primer so as to identify the two wildtype and two mutant sequences (see Supplementary table  
137 4 for primer and tag sequences). The PCR products were purified with Sureclean and sent in  
138 for Pacbio Sequel circular consensus sequencing with a library insert size of 2kb.

139 Pacbio IsoSeq files were error-corrected and converted into CCS reads; We performed 10  
140 minimum passes with a minimum predicted accuracy of 0.9 using the PacBio SMRT analysis  
141 software (v5.1.0). The analysis generated 225,740 CCS reads with a median CCS read length  
142 between 1200 – 1249 bp (see Supplementary Figure 5 for results statistics).

143 The reads were then demultiplexed using Geneious with a 100% stringency match to primer  
144 and tag sequences. The demultiplexed sequences were then filtered for low read length (<  
145 500bp) yielding 18194 reads for M4, 124385 reads for M6, 13422 reads for WT1 and 18817  
146 reads for WT2. For each individual, the reads were collapsed into haplotypes using the ‘DNA  
147 to Haplotype converter’ tool in FaBox (Villesen, 2007). Haplotypes with read counts below  
148 0.5% of the total count were discarded. The remaining haplotypes were aligned using  
149 MAFFT v7.0 and then analysed in Aliview to identify alternative splice forms (alignment  
150 files in Mendeley resource).

### 151 **Distal-less expression in developing histoblast clusters**

152 To determine if *Dll* was naturally expressed in the 3<sup>rd</sup> abdominal segment where an ectopic  
153 sternite brush was observed, RNA was extracted from dissected epidermal tissues of 3<sup>rd</sup> instar  
154 larvae. The epidermis of the thoracic segment and the abdominal segments (8 abdominal  
155 segments for *D. melanogaster* and 7 abdominal segments for *T. biloba*) were dissected for 5  
156 wildtype 3<sup>rd</sup> instar larvae for both *T. biloba* and *D. melanogaster*. RNA was extracted for  
157 each segment and cDNA was synthesised. RT PCR for *Dll* was carried out for each segment  
158 to check for *Dll* expression in the late larval stages.

159 The same was done for *D. melanogaster*, which served as a control for the RT-PCR  
160 experiment. RT- PCR for an additional gene, Abdominal-B, was also carried out in *D.*  
161 *melanogaster* as a control to rule out the presence of any artefacts from the epidermal  
162 dissections. All PCR products were then PCR purified and sent in for sanger sequencing to  
163 confirm the correct products were amplified (results in Supplementary Table 5,  
164 Supplementary Figure 4).

### 165 **Distal-less alignment across Holometabola**

166 A protein search performed on NCBI using the following search terms “Distal-less[All  
167 Fields] AND (“Mandibulata”[Organism] OR Mandibulata[All Fields])” yielded 467 protein  
168 sequences. This dataset was filtered for sequences that: were not Distal-less, had no  
169 homeodomain, were incomplete or of poor quality. Sequences belonging to Coleoptera,

170 Lepidoptera, Diptera and Hymenoptera were extracted from the filtered dataset and aligned  
171 with MAFFT v7.0(Katoh et al., 2002) and visualised in Aliview (Larsson, 2014).

## 172 **Quantitative PCR**

173 We injected embryos with both Cas9 and the guide targeting Exon 2 and compared  
174 expression levels to control embryos that were injected with Cas9 alone. We let embryos  
175 develop into first instar larvae. All control larvae were individually extracted for RNA using  
176 Trizol. All treatment larvae were first genotyped to confirm presence of mutations in Exon 2  
177 using the T7 endonuclease kit (New England Biolabs). RNA from mutant larvae was then  
178 used for cDNA synthesis to generate template for qPCR. The Forkhead transcription factor  
179 (Mnf) gene was used as a housekeeping gene. We utilised a customised TaqMan gene  
180 expression assay with primers nested within the homeodomain and with a probe  
181 complementary to the homeodomain. The expression levels were not significantly different  
182 between wildtype and mutant larvae. However, note that CRISPR/Cas9 generates mosaic  
183 mutants that consist mostly of wildtype cells and mutants that survive are likely to only have  
184 small amounts of mutant cells. This makes it difficult to disentangle expression levels  
185 between wildtype mRNA from wildtype cells and exon-skipped transcripts of mutant cells.  
186 With naturally low *Dll* expression (Ct value > 30), a lack of significant expression difference  
187 is inconclusive.

## 188 **Data availability**

189 Most of the processed sequencing data files are available on a Mendeley database (DOI:  
190 10.17632/ps3p7jnb5t.1). However, for pre-filtered/processed files and other data, please  
191 contact Rajaratnam, G. For the in-house bioinformatics script, please contact Meier, R.

## 192 **References**

- 193 CARTEGNI, L., WANG, J., ZHU, Z., ZHANG, M. Q. & KRAINER, A. R. 2003. ESEfinder:  
194 a web resource to identify exonic splicing enhancers. *Nucleic Acids Research*, 31,  
195 3568-3571.
- 196 COHEN, S. M. & JÜRGENS, G. 1989. Proximal—distal pattern formation in *Drosophila*:  
197 cell autonomous requirement for Distal-less gene activity in limb development. *The*  
198 *EMBO Journal*, 8, 2045-2055.
- 199 GONZALEZ-GARAY, M. L. 2016. Introduction to Isoform Sequencing Using Pacific  
200 Biosciences Technology (Iso-Seq). In: WU, J. (ed.) *Transcriptomics and Gene*  
201 *Regulation*. Dordrecht: Springer Netherlands.
- 202 KATOH, K., MISAWA, K., KUMA, K.-I. & MIYATA, T. 2002. MAFFT: a novel method  
203 for rapid multiple sequence alignment based on fast Fourier transform. *Nucleic Acids*  
204 *Research*, 30, 3059-3066.



205 LARSSON, A. 2014. AliView: a fast and lightweight alignment viewer and editor for large  
206 datasets. *Bioinformatics*, 30, 3276-3278.

207 MEIER, R., WONG, W., SRIVATHSAN, A. & FOO, M. 2016. \$1 DNA barcodes for  
208 reconstructing complex phenomes and finding rare species in specimen-rich samples.  
209 *Cladistics*, 32, 100-110.

210 MELICHER, D., TORSON, A. S., DWORKIN, I. & BOWSHER, J. H. 2014. A pipeline for  
211 the de novo assembly of the *Themira biloba*(Sepsidae: Diptera) transcriptome using a  
212 multiple k-mer length approach. *BMC Genomics*, 15, 188.

213 PINELLO, L., CANVER, M. C., HOBAN, M. D., ORKIN, S. H., KOHN, D. B., BAUER, D.  
214 E. & YUAN, G.-C. 2016. Analyzing CRISPR genome-editing experiments with  
215 CRISPResso. *Nat Biotech*, 34, 695-697.

216 SMITH, P. J., ZHANG, C., WANG, J., CHEW, S. L., ZHANG, M. Q. & KRAINER, A. R.  
217 2006. An increased specificity score matrix for the prediction of SF2/ASF-specific  
218 exonic splicing enhancers. *Hum Mol Genet*, 15, 2490-508.

219 VILLESSEN, P. 2007. FaBox: an online toolbox for fasta sequences. *Molecular Ecology*  
220 *Notes*, 7, 965-968.

221 ZHANG, J., KOBERT, K., FLOURI, T. & STAMATAKIS, A. 2014. PEAR: a fast and  
222 accurate Illumina Paired-End reAd mergeR. *Bioinformatics*, 30, 614-620.

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239


240

241

242 **Figures**

243

244




245

246 **Figure 1**

247

248

249




250

251 **Figure 2**

252


253

254  
255



256  
257  
258

**Figure 3.**




259

260 **Figure 4**

261

262



263


264

**Figure 5**

265

266


267



268


269

**Figure 6**



270

271 **Figure 7**



272

273 **Figure 8**

274

275

## 276 Tables

277

278 **Table 1.**

279

	Injected eggs	Larvae	Adults	Mutants			
				Leg/Wing	Sternite malformations	Ectopic structures	Others (e.g. clasper malformations)
Exon 2 (sgRNA 2A)	1715	605	151	1	8	1	0
Exon 2 (sgRNA 2B)	4631	957	363	8	29	3	6
Exon 3 (sgRNA3)	4003	1187	261	1	21	0	2
Control	1004	153	109	0	0	0	0

280 **Supplementary information**

281

282 **Supplementary Table 1.** Summary of ESEfinder search with Matrix values for SRSF1  
 283 (human homolog for SF2/ASF) with threshold of 1.956. The ESE motif present in Exon 2  
 284 sgRNA-2B is highlighted in bold while the ESE motif used to design sgRNA-2A is italicized.  
 285 Related to Figure 4.

Sequence ID	Motif	Position on Exon 2	Motif	Score
gi 654231031 gb GBGG01003309.1	<b>SRSF1</b>	<b>100</b>	<b>cgcccat</b>	<b>2.21734</b>
<i>gi 654231031 gb GBGG01003309.1 </i>	<i>SRSF1</i>	<i>17</i>	<i>cagcggg</i>	<i>4.39195</i>
gi 654231031 gb GBGG01003309.1	SRSF1	49	gtcagga	3.28514
gi 654231031 gb GBGG01003309.1	SRSF1	75	cgcagtg	2.69094
gi 654231031 gb GBGG01003309.1	SRSF1	15	cgcagcg	2.23323
gi 654231031 gb GBGG01003309.1	SRSF1	169	caaagga	3.67496

286

287 **Supplementary Table 2.** Summary of blastn results. Related to Figure 4.

Query	Number of HSPs	Lowest E-value	Accession (E-value)	Greatest identity %	Greatest HSP length	Greatest bit score	Sequence overlap with guide %
gi 654231031 gb GBGG01003309.1  ( <i>Themira biloba</i> DII)	1	1.38661E-06	sgRNA-2B	100	20	32.7626	100
gi 654228759 gb GBGG01004492.1	1	0.0066504	sgRNA-2B	100	13	21.9569	65
gi 654228161 gb GBGG01004814.1	1	0.00242708	sgRNA-2B	100	13	21.9569	65
gi 654223893 gb GBGG01007092.1	1	0.00259143	sgRNA-2B	100	13	21.9569	65

288

289 **Supplementary Table 3.** Summary of read counts for mutant haplotypes. The 3 most  
 290 dominant mutant haplotypes per individual are recorded here. The dominant haplotype (in  
 291 bold) per individual is used for downstream analyses. See separate excel document. Related  
 292 to Figure 2, 3, 4 and 7.

293

294

295

296



297 **Supplementary Table 4.** Primer sequences. Tags are in lower case. Related to Figure 2, 3, 4,  
 298 5, 7 and 8.

Purpose	Name	Primer sequence (5' → 3')
Characterisation of homeodomain mutants	Dll_sgrna12_F1	cagtctgGACAAATGCGAAGATTCTGG
Characterisation of homeodomain mutants	Dll_sgrna12_F2	catgggaGACAAATGCGAAGATTCTGG
Characterisation of homeodomain mutants	Dll_sgrna12_F3	tcacgtaGACAAATGCGAAGATTCTGG
Characterisation of homeodomain mutants	Dll_sgrna12_F4	tggccaGACAAATGCGAAGATTCTGG
Characterisation of homeodomain mutants	Dll_sgrna12_F5	aacctgtGACAAATGCGAAGATTCTGG
Characterisation of homeodomain mutants	Dll_sgrna12_F6	cttggttGACAAATGCGAAGATTCTGG
Characterisation of homeodomain mutants	Dll_sgrna12_R1	cagtctgCTGCGTTTGTGTTAGGCCCA
Characterisation of homeodomain mutants	Dll_sgrna12_R2	catgggaCTGCGTTTGTGTTAGGCCCA
Characterisation of homeodomain mutants	Dll_sgrna12_R3	tcacgtaCTGCGTTTGTGTTAGGCCCA
Characterisation of homeodomain mutants	Dll_sgrna12_R4	tggccaCTGCGTTTGTGTTAGGCCCA
Characterisation of homeodomain mutants	Dll_sgrna12_R5	aacctgtCTGCGTTTGTGTTAGGCCCA
Characterisation of homeodomain mutants	Dll_sgrna12_R6	cttggttCTGCGTTTGTGTTAGGCCCA
Characterisation of Exon 2 mutants	Dll_sgrna4_F1	aacctgtTACGGTGGCATTTCGCAGCGGT TATC
Characterisation of Exon 2 mutants	Dll_sgrna4_F2	agaagtgtTACGGTGGCATTTCGCAGCGG TTATC
Characterisation of Exon 2 mutants	Dll_sgrna4_F3	cggttatTACGGTGGCATTTCGCAGCGGT TATC
Characterisation of Exon 2 mutants	Dll_sgrna4_F4	gtacactTACGGTGGCATTTCGCAGCGGT TATC
Characterisation of Exon 2 mutants	Dll_sgrna4_F5	gtgatgaTACGGTGGCATTTCGCAGCGG TTATC
Characterisation of Exon 2 mutants	Dll_sgrna4_F6	cttggttTACGGTGGCATTTCGCAGCGGT TATC
Characterisation of Exon 2 mutants	Dll_sgrna4_R1	aacctgtGGGCTCGCACATGGCGGG
Characterisation of Exon 2 mutants	Dll_sgrna4_R2	agaagtgtGGGCTCGCACATGGCGGG
Characterisation of Exon 2 mutants	Dll_sgrna4_R3	cggttatGGGCTCGCACATGGCGGG
Characterisation of Exon 2 mutants	Dll_sgrna4_R4	gtacactGGGCTCGCACATGGCGGG

Characterisation of Exon 2 mutants	Dll_sgrna4_R5	gtgatgaGGGCTCGCACATGGCGGG
Characterisation of Exon 2 mutants	Dll_sgrna4_R6	cttggttGGGCTCGCACATGGCGGG
Characterisation of ESE mutants	Dll_intron1_F1	aacctgtGTTGTGCCTCCAAGGATTTCATAC
Characterisation of ESE mutants	Dll_intron1_F2	agaagtg GTTGTGCCTCCAAGGATTTCATAC
Characterisation of ESE mutants	Dll_intron1_F3	cggttat GTTGTGCCTCCAAGGATTTCATAC
Characterisation of ESE mutants	Dll_intron1_F4	gtacact GTTGTGCCTCCAAGGATTTCATAC
Characterisation of ESE mutants	Dll_intron1_F5	gtgatga GTTGTGCCTCCAAGGATTTCATAC
Characterisation of ESE mutants	Dll_intron1_F6	cttggtt GTTGTGCCTCCAAGGATTTCATAC
Characterisation of ESE mutants	Dll_sgrna4_R1	aacctgtGGGCTCGCACATGGCGGG
Characterisation of ESE mutants	Dll_sgrna4_R2	agaagtgGGGCTCGCACATGGCGGG
Characterisation of ESE mutants	Dll_sgrna4_R3	cggttatGGGCTCGCACATGGCGGG
Characterisation of ESE mutants	Dll_sgrna4_R4	gtacactGGGCTCGCACATGGCGGG
Characterisation of ESE mutants	Dll_sgrna4_R5	gtgatgaGGGCTCGCACATGGCGGG
Characterisation of ESE mutants	Dll_sgrna4_R6	cttggttGGGCTCGCACATGGCGGG
Amplification of <i>Dll</i> in <i>Drosophila melanogaster</i>	Dmel_Dll_F2	CCGATAAGTGCGAGGACTCCGG
Amplification of <i>Dll</i> in <i>Drosophila melanogaster</i>	Dmel_Dll_R	CTGCGTTTGCGTGAGGCCCA
Amplification of <i>Abd-B</i> in <i>Drosophila melanogaster</i>	Dmel_ABDB_44_2_F	CCCACCTACTCCTCGCCAGGCGG
Amplification of <i>Abd-B</i> in <i>Drosophila melanogaster</i>	Dmel_ABDB_57_1_R	TCCACTCGTGCAGTCCGGGATTGGGC
Shortened reverse primer with lower Tm for cycle sequencing of <i>Drosophila melanogaster</i> Abd-B amplicon	Dmel_ABDB_57_1_SEQ_R	TCCACTCGTGCAGTCCGGGATT
Amplification of <i>Dll</i> in <i>Themira biloba</i>	DLL Exon 2 sgRNA4 F	TAC GGT GGC ATT CGC AGC GGT TAT C
Amplification of <i>Dll</i> in <i>Themira biloba</i>	DLL Exon 2 sgRNA4 R	CAC ATG GCG GGG CAT AAC TGC CTA AAT G

Amplification of Dll for isoform sequencing	DLL 5'UTR Pacbio F	/5Phos/CAC GCT TAA TTT CAC AGA TTT AGG GAG CCC C
Amplification of Dll for isoform sequencing	DLL exon 7 Pacbio R1	/5Phos/tca gac gat gcg tca tAG GTG GAG GTG GTA ATT GCG GCG AAT GG
Amplification of Dll for isoform sequencing	DLL exon 7 Pacbio R2	/5Phos/cta tac atg act ctg cAG GTG GAG GTG GTA ATT GCG GCG AAT GG
Amplification of Dll for isoform sequencing	DLL exon 7 Pacbio R3	/5Phos/tac tag agt agc act cAG GTG GAG GTG GTA ATT GCG GCG AAT GG
Amplification of Dll for isoform sequencing	DLL exon 7 Pacbio R4	/5Phos/tgt gta tca gta cat gAG GTG GAG GTG GTA ATT GCG GCG AAT GG
Generating exon-skipped template for protein in vitro synthesis	Tbil Dll start codon F	GCGAATTAATACGACTCACTATAGG GCTTAAGTATAAGGAGGAAAAAAT ATGGATGCGCCCGATGCACCGCATA C
Generating exon-skipped template for protein in vitro synthesis	Tbil Dll stop codon R	AAACCCCTCCGTTTAGAGAGGGGTT ATGCTAGTTATTAGTGGTGGTGGTG GTGGTGAAGTCCCGGCCACACCGTT AATAGCGATGG

299

300 **Supplementary Table 5.** Sanger sequencing results for the RT-PCR to determine *Distal-less*  
301 expression in developing histoblast clusters. See separate excel document. Related to Figure  
302 7.

303 **Supplementary Table 6.** Target region sequences for single guide RNA for CRISPR/Cas9  
304 genome editing. Related to Figure 2, 3, 4 and 7.

sgRNA	Target sequence (5' → 3')
sgRNA-2A	GGTTACGGTGGCATTTCGCAGCGG
sgRNA-2B	GGAATAGGAATTCTGATGCATGG
sgRNA-3	GGTTTCAACGCACCCAGTATTTGG

305

306

307

308

309

310

311

312

313

314

315

316

317

318


319

320



321


322 **Supplementary Figure 1.** Deletions in *Dll* Exon 2 produce mosaic mutant (E2B M8) with  
323 loss of the 4<sup>th</sup> sternite brush. Related to Figure 4.



324

325 **Supplementary Figure 2.** Alignment of *Distal-less* protein sequences across holometabola.  
 326 Alignment in fasta format is provided in the Mendeley resource. Related to Figure 4.

327



328


329 **Supplementary Figure 3.** Fragmentation evidence for *Dll* peptides recovered from  
 330 ProteinPilot. (a) Fragment ion mass values and peptide peak intensity for ‘QSTWMAAQR’, a  
 331 peptide matching to an alternative initiation codon (b), (c), (d) and (e) Fragment ion mass  
 332 values and peptide peak intensity for peptides matching to *Dll* homeodomain. Related to  
 333 Figure 6.

334

335

336

337




338

339 **Supplementary Figure 4.** RT-PCR results to determine *Dll* expression in late larval  
340 epidermal tissues. *Drosophila melanogaster* was used as a control. Primers for this  
341 experiment are found in Supplementary Table 5. Identity of amplified products were  
342 confirmed with sanger sequencing (results in Supplementary Table 6). A1-A8: Tissue from  
343 the respective abdominal epidermal segments. T: Tissue from the thoracic epidermal  
344 segment. (a) In the control, *D.melanogaster*, Abd-B is present and amplified in the 5<sup>th</sup> – 8<sup>th</sup>  
345 abdominal segments as expected. (b) *Dll* is present and amplified in all 8 abdominal segments  
346 in *D.melanogaster* (c) *Dll* is present and amplified in all 7 abdominal segments in *Themira*  
347 *biloba*. Related to Figure 7.

348

349  
350  
351  
352



353  
354

355 **Supplementary Figure 5.** Read length distribution of Pacbio Iseq error-corrected reads (10  
356 minimum passes with a minimum predicted accuracy of 0.9) using the PacBio SMRT  
357 analysis software (v5.1.0). The analysis generated 225,740 CCS reads with a median CCS  
358 read length between 1200 – 1249 bp. Related to Figure 8.

359  
360



361

362

363

364

365

366

367